摘要
Rivaroxaban,a direct oral anticoagulant,has proven efficacy and safety at its standard dose in the treatment and prevention of various vascular conditions.These include the treatment of venous thromboembolism and stroke prevention in non-valvular atrial fibrillation.A"very low"vascular dose of rivaroxaban,when combined with low-dose aspirin,has been demonstrated to reduce major adverse cardiovascular events,including stroke,in both acute and chronic coronary syndrome.The combination of rivaroxaban and low-dose aspirin could potentially offer an additional strategy for stroke prevention in selected non-atrial fibrillation patients who are at a high risk of stroke.
